Napa Parinyanitikul

Final Results of RIGHT Choice: Ribociclib Plus Endocrine Therapy Versus Combination Chemotherapy in Premenopausal Women With Clinically Aggressive Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer

Yen‐Shen Lu, Eznal Izwadi Bin Mohd Mahidin, Hamdy A. Azim et al. · Journal of Clinical Oncology · 2024 · 65 citations · Full text

cMET Activation and EGFR-Directed Therapy Resistance in Triple-Negative Breast Cancer

Joohyuk Sohn, Shuying Liu, Napa Parinyanitikul et al. · Journal of Cancer · 2014 · 56 citations · Full text

Mesothelin Expression and Survival Outcomes in Triple Receptor Negative Breast Cancer

Napa Parinyanitikul, George R. Blumenschein, Yun Wu et al. · Clinical Breast Cancer · 2013 · 49 citations · Full text

Survival Outcomes, Breast Oncology, Medicine +8

Receptor Status Change From Primary to Residual Breast Cancer After Neoadjuvant Chemotherapy and Analysis of Survival Outcomes

Napa Parinyanitikul, Xiudong Lei, Mariana Chávez‐MacGregor et al. · Clinical Breast Cancer · 2014 · 46 citations

Surgical Oncology, Survival Outcomes, Breast Oncology +7

Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, staging and treatment of patients with metastatic breast cancer

Seock‐Ah Im, Alessandra Gennari, Y.H. Park et al. · ESMO Open · 2023 · 43 citations · Full text